Abbott Laboratories stock falls as sentiment turns cautious on weaker sales growth forecast

Traders Union
All News
Stocks
Abbott Laboratories slides 3.57% today

Highlights

Abbott Laboratories reduced its full-year comparable sales growth forecast to about 6 percent and reaffirmed adjusted EPS guidance.
The company maintained its plan to keep combined dividend payouts after the proposed Nutrition division spin-off and received clearance to sell its Cologuard Plus test in select European markets.
Shares of Abbott stock trade below major moving averages with momentum signals mixed and a projected range of $96.51 to $101.07, with a high probability of further decline.

Sales forecast cut pressures sentiment despite steady earnings and new approvals

Abbott Laboratories lowered its full-year comparable sales growth forecast to approximately 6 percent, reflecting a more cautious outlook on near-term commercial performance. Q3 2026 financial results showed revenue and adjusted EPS roughly in line with market consensus, with the company also reaffirming its full-year adjusted EPS outlook, according to Rttnews. The company announced plans to maintain combined dividend payouts after its planned Nutrition division spin-off, and received CE Mark clearance for its Cologuard Plus colorectal cancer test under the EU In Vitro Diagnostic Regulation, permitting sales in select European markets. Despite these developments, the adjustment to sales growth guidance has weighed more heavily on sentiment.

Mixed momentum as resistance levels and indicators contradict

On the technical side, ABT is trading below the MA-20 ($103.73) and MA-50 ($103.23) on the hourly chart, and remains under the MA-200 ($102.59) on the daily timeframe. The Ichimoku Kijun at $103.34 functions as immediate resistance. Momentum indicators show a mixed picture: MACD points to a sell bias, while ADX notes underlying buying strength. RSI registers at 59.58 (Buy), but both Stochastic RSI and Bull/Bear Power signal overbought conditions, and CCI delivers a neutral reading. The Awesome Oscillator maintains a downward tone, highlighting divergence among signals and suggesting caution is warranted.

Downside risk prevails as consolidation dominates near-term outlook

Over the next several sessions, ABT is expected to range between $96.51 and $101.07, representing a typical volatility band relative to current levels. There is a high probability of further downside (77%), while the chance of a rebound is lower (23%). The base case remains for consolidation. A bullish reversal scenario would require a breakout above the Ichimoku Kijun resistance, while a break below forecasted support could prompt additional weakness.

Anton Kharitonov, Analyst at Traders Union, sees persistent downside in Abbott Laboratories as lowered sales growth guidance has dampened market sentiment. Technical signals are mixed, but the stock remains under key resistance levels and downside risk dominates the short-term outlook. He believes news of the dividend commitment and regulatory clearance is not enough to offset weaker fundamentals. "Cautious positioning is warranted here — as long as price action stays below $103.34, I’m watching for further weakness or consolidation."

Earlier, analysts noted that mixed technical readings and persistent volatility kept Abbott Laboratories shares in a cautious holding pattern, with downside risks dominating the outlook. The current analysis reinforces this view, highlighting a continued bias toward consolidation with a significant probability of further weakness unless a sustained breakout above immediate resistance is achieved.

Source of Data: ABT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.